We are already making a national impact in several key areas that transform the drug discovery sector, such as the development of high-tech lab-based models of disease, advanced clinical imaging techniques, and targeting hard-to-treat diseases like antimicrobial resistance, cystic fibrosis and diseases associated with ageing.
We have helped UK companies advance their drugs into patient trials and their technology products on the market. Our R&D partners have raised over £1.34bn in private investment.
Focusing on the hard-to-do will enable innovators to de-risk their products and services, making them and the country successful and improving patient outcomes.
